Companies › Corxel Pharmaceuticals
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CX11 | – | Phase 2 | Type II Diabetes Mellitus; Obesity & Overweight | Mar 2027 |
| JX10 Thrombolytic agent | – | Phase 2 | Acute Ischemic Stroke | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07652047 | CX11 | Phase 1 | Obesity & Overweight | Metabolic and endocrine | Mar 2027 |
| NCT07340320 | CX11 | Phase 2 | Type II Diabetes Mellitus | Metabolic and endocrine | Apr 2027 |
| NCT06990867 | JX10 | Phase 2 | Acute Ischemic Stroke | Neurology | Oct 2029 |
No annotated target.
–
Shenzhen Wingor Biotechnology NeuroBiogen Urovant Sciences MediciNova PRG Science & Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.